SCHEMBL2213765

SCHEMBL2213765

CNC(=O)c1ccc(C)c(-c2ncc(NC(=O)C(C)NC)c(=O)n2Cc2cc(Cc3ccc(F)cc3)cc(N3CCCC3)c2)c1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CACNA1G O43497 4/20 0.36
MAPK14 Q16539 5/20 0.34
MCHR1 Q99705 2/20 0.34
HTR2C P28335 1/20 0.34
SCN9A Q15858 1/20 0.34
MAPT P10636 2/20 0.33
NAMPT P43490 1/20 0.33
TP53 P04637 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
HPGD P15428 1/20 0.33
EHMT2 Q96KQ7 1/20 0.33
KMT2A Q03164 1/20 0.33
LCK P06239 1/20 0.32
KDR P35968 1/20 0.32
JAK3 P52333 1/20 0.32
KDM4E B2RXH2 1/20 0.32
NPC1 O15118 1/20 0.32
ALDH1A1 P00352 1/20 0.32
LMNA P02545 1/20 0.32
RAB9A P51151 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2213757 1.00 CACNA1G (0.36) CACNA1GMAPK14MCHR1HTR2CSCN9A
SCHEMBL2212137 0.93 WDR5 (0.34) CACNA1GMAPK14MCHR1HTR2CSCN9A
SCHEMBL2212130 0.93 WDR5 (0.34) CACNA1GMAPK14MCHR1HTR2CSCN9A
SCHEMBL2209797 0.84 MAPK14 (0.36) MAPK14HPGDKDM4EALDH1A1PTGER4
SCHEMBL2209792 0.84 MAPK14 (0.36) MAPK14HPGDKDM4EALDH1A1PTGER4
SCHEMBL2209907 0.82 SCN9A (0.36) MCHR1HTR2CSCN9AMAPTNAMPT
SCHEMBL2209899 0.82 SCN9A (0.36) MCHR1HTR2CSCN9AMAPTNAMPT
SCHEMBL2210663 0.82 MAPK14 (0.34) MAPK14HPGDALDH1A1
SCHEMBL2211289 0.82 MAPK14 (0.34) MAPK14HPGDALDH1A1
SCHEMBL1323886 0.81 WDR5 (0.34) CACNA1GMAPK14MAPTTP53SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2099769-B1 6-OXO.-1, 6-DIHYDROPYRIMIDIN-2-YLS IN THE TREATMENT OF PROLIFERATIVE DISEASES NOVARTIS AG (CH) 2011-07-27 EP claimed